Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Pfizer Pushes to Keep Lipitor Profits Flowing

Efforts to preserve the lucrative cholesterol-drug's franchise have sparked an antitrust suit. But competition is inevitable.

Amylin Stumbles After Lilly Pulls Partnership Plug

As Eli Lilly looks elsewhere for a diabetes drug partner, Amylin Pharmaceuticals stumbles. But Lilly is happy as can be. Here's why.

Hepatitis C Drug Progress Puts Several Companies on Acquisition Watch

With their hepatitis C drugs showing promise in trials, these drug makers have become attractive targets for bigger pharma players.

Medivation Shares Shoot Up on Prostate Cancer Treatment News

Medivation (MDVN) gains almost 140% Thursday on encouraging results for its prostate cancer treatment, and Dendreon (DNDN) is further battered.

Why Dendreon Is Aiming Prostate Drug Pitches to Consumers

Dendreon (DNDN) appears to be pulling out all the stops in an effort to restore at least some of the luster to its prostate cancer treatment Provenge.